neurogenic detrusor overactivity

Updated: November 25, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

mirabegron

<3 years: Safety and efficacy not established
≥3 years: Weight <35kg
Oral suspension granules
11kg to <22kg: 24mg orally every day, initially up to 48mg/day
22 to <35kg: 32mg orally every day, initially up to 64mg/day
≥3 years: Weight >35kg
25mg orally every day up to 50mg orally
Oral suspension granules: 48mg orally every day, initially up to 80mg/day

fesoterodine

Age: ≥6 years 
Weight: >25-35 kg 
4 mg orally every day; can increase dose up to 8 mg per day as needed
Age: ≥6 years
Weight: >35 kg 
4 mg orally every day; can increase dose up to 8 mg per day after one week 

Future Trends